Javascript must be enabled to continue!
A preliminary study of the association between Blastocystis and quantification of selected yeasts in IBD and IBS patients
View through CrossRef
ObjectiveIrritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) are gastrointestinal disorders, which can be triggered by gut microbiota dysbiosis. The development of IBS-like symptoms has been linked to the overgrowth of Candida spp. In addition, the critical role of fungi has been highlighted in the pathogenesis of IBD. This study investigated the association between Blastocystis and selected yeasts in IBS and IBD patients.MethodsThis investigation is a cross-sectional study from 2022 to 2024, performed on 91 participants, including 20 healthy individuals, 27 patients with IBS, and 44 IBD patients [39 with ulcerative colitis (UC; 88.63%) and 5 (11.37%) Crohn’s disease (CD)], who were also categorized based on the presence of Blastocystis. Total DNA was extracted from stool samples, and the presence and quantity of yeasts including C. albicans, C. tropicalis, C. glabrata, C. parapsilosis, C. krusei, Geotrichum candidum, Rhodotorula spp., Cryptococcus neoformans, and Saccharomyces cerevisiae were evaluated by real-time PCR. Statistical tests were used to assess significant associations between variables.ResultsSaccharomyces cerevisiae and C. albicans were the most prevalent yeasts in all groups. Candida tropicalis and C. neoformans were identified in neither patients nor healthy subjects. The presence/absence of C. albicans was not significantly different between patients with IBD, IBS, and the control groups. This was similar for G. candidum. However, there was a difference in the presence of S. cerevisiae among patients, although it was insignificant (p-value = 0.077). There was a significant difference in the quantity of C. albicans between IBD (880.421 ± 2140.504), IBS (10.307 ± 15.206), and controls (2875.888 ± 8383.889) (p-value = 0.020). Specifically, the source of difference was seen between IBD patients and the control group (p-value = 0.005). In addition, considering the presence of Blastocystis, a statistically significant association was seen between the number of C. albicans and the sample groups (p-value = 0.013). The quantity of C. albicans was significantly different between IBS and IBD patients.ConclusionRegarding the presence of Blastocystis, the quantity of C. albicans and S. cerevisiae was increased and decreased in the studied groups, respectively. This is a preliminary study, and eukaryote–eukaryote association in IBS and IBD patients should be considered in further studies.
Title: A preliminary study of the association between Blastocystis and quantification of selected yeasts in IBD and IBS patients
Description:
ObjectiveIrritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) are gastrointestinal disorders, which can be triggered by gut microbiota dysbiosis.
The development of IBS-like symptoms has been linked to the overgrowth of Candida spp.
In addition, the critical role of fungi has been highlighted in the pathogenesis of IBD.
This study investigated the association between Blastocystis and selected yeasts in IBS and IBD patients.
MethodsThis investigation is a cross-sectional study from 2022 to 2024, performed on 91 participants, including 20 healthy individuals, 27 patients with IBS, and 44 IBD patients [39 with ulcerative colitis (UC; 88.
63%) and 5 (11.
37%) Crohn’s disease (CD)], who were also categorized based on the presence of Blastocystis.
Total DNA was extracted from stool samples, and the presence and quantity of yeasts including C.
albicans, C.
tropicalis, C.
glabrata, C.
parapsilosis, C.
krusei, Geotrichum candidum, Rhodotorula spp.
, Cryptococcus neoformans, and Saccharomyces cerevisiae were evaluated by real-time PCR.
Statistical tests were used to assess significant associations between variables.
ResultsSaccharomyces cerevisiae and C.
albicans were the most prevalent yeasts in all groups.
Candida tropicalis and C.
neoformans were identified in neither patients nor healthy subjects.
The presence/absence of C.
albicans was not significantly different between patients with IBD, IBS, and the control groups.
This was similar for G.
candidum.
However, there was a difference in the presence of S.
cerevisiae among patients, although it was insignificant (p-value = 0.
077).
There was a significant difference in the quantity of C.
albicans between IBD (880.
421 ± 2140.
504), IBS (10.
307 ± 15.
206), and controls (2875.
888 ± 8383.
889) (p-value = 0.
020).
Specifically, the source of difference was seen between IBD patients and the control group (p-value = 0.
005).
In addition, considering the presence of Blastocystis, a statistically significant association was seen between the number of C.
albicans and the sample groups (p-value = 0.
013).
The quantity of C.
albicans was significantly different between IBS and IBD patients.
ConclusionRegarding the presence of Blastocystis, the quantity of C.
albicans and S.
cerevisiae was increased and decreased in the studied groups, respectively.
This is a preliminary study, and eukaryote–eukaryote association in IBS and IBD patients should be considered in further studies.
Related Results
Investigating Significant Issues of BIM Implementation in Industrialised Building System Design and Production Process
Investigating Significant Issues of BIM Implementation in Industrialised Building System Design and Production Process
Industrialised Building System (IBS) has been considered a construction method to accelerate the development of the construction industry in attempt to boost the econo...
An Inflammatory Bowel Diseases Integrated Resources Portal (IBDIRP)
An Inflammatory Bowel Diseases Integrated Resources Portal (IBDIRP)
Abstract
IBD, including ulcerative colitis and Crohn’s disease, is a chronic and debilitating gastrointestinal disorder that affects millions of people worldwide. Re...
P125 Ankylosing spondylitis can influence the outcome of inflammatory bowel disease
P125 Ankylosing spondylitis can influence the outcome of inflammatory bowel disease
Abstract
Background
Both inflammatory bowel disease (IBD) and ankylosing spondylitis (AS) are inflammatory diseases but there wa...
Mortality and morbidity outcomes in patients with inflammatory bowel disease with colon cancer: A nationwide analysis.
Mortality and morbidity outcomes in patients with inflammatory bowel disease with colon cancer: A nationwide analysis.
e15669
Background:
Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is a chronic condition chara...
A comparison using standardized measures for patients with irritable bowel syndrome: Trust in the gastroenterologist and reliance on the internet
A comparison using standardized measures for patients with irritable bowel syndrome: Trust in the gastroenterologist and reliance on the internet
AbstractBackgroundIrritable bowel syndrome (IBS) patients’ use of the Internet for health information interacts with the way they trust their gastroenterologist. No standardized me...
Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea‐predominant irritable bowel syndrome
Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea‐predominant irritable bowel syndrome
AbstractBackground The intestinal microbiota has been implicated in the pathophysiology of irritable bowel syndrome (IBS). Due to the variable resolutions of techniques used to ch...
Development and psychometric testing of the Visual Analogue Scale for Irritable Bowel Syndrome (VAS-IBS)
Development and psychometric testing of the Visual Analogue Scale for Irritable Bowel Syndrome (VAS-IBS)
Background: The aim of this study was to develop and psychometrically test a short, patient-reported questionnaire to be used in clinical practice for patients with Irritable Bowel...
Clinical stigmas of irritable bowel syndrome associated with obesity and overweight
Clinical stigmas of irritable bowel syndrome associated with obesity and overweight
Objective. To identify clinical stigmas and eating habits of patients with irritable bowel syndrome (IBS) against the background of overweight and obesity in order to improve the e...

